I believe this is to improve performance by shortening the context window for long thinking processes. I don't think this is referring to real-time summarizing for the users' sake.
For example, in the recent Phase 2b CB1 agonist for cannabis user disorder from AELIS, the FDA required a standard of efficacy of an 80% reduction in use. The trial failed for unrelated reasons, but many researchers in the field have expressed frustration that this requirement, a reduction far beyond what will improve a patient’s health, sends a negative signal to other companies interested in advancing effective addiction treatments.
I’ve lost 60 pounds and my health has improved considerably. I was overeating out of boredom and stress. I’ve been able to reduce my blood pressure medication. My blood sugar is much more controlled. I started riding a recumbent bike for an hour and a half a day due to concerns of losing muscle along with fat.
A new, large retrospective study of patient health records shows a 40% drop in opioid overdoses and a 50% drop in cases of alcohol intoxication among people who received GLP-1RAs (typically for diabetes or obesity).
"These findings provide compelling evidence that acute alcohol consumption decreases GLP-1, a satiation signal, elucidating alcohol's 'apéritif' effect." This could increase hunger and cravings (including for more alcohol).
This shape, known since at least Plato's time and named by Kepler, has fascinated thinkers from Archimedes to Buckminster Fuller. As its name implies, it's somewhere between a cube and an octahedron, taking six and eight of its 14 sides from each of those respectively. It's rounder than either of those shapes though, making it a much better vessel for salt, olives, or weed.
"Because the pharma companies with approved GLP-1s do not pursue addiction treatment, a large scale trial and FDA indication will not happen on its own. Without a strategic public effort along these lines, we may be waiting 10-15 years before a GLP-1 indication becomes available.
If we are successful in launching large-scale studies, this will be an unprecedented non-profit scientific endeavor, filling the gap between public research agencies and pharma, and collaborating with both along the way. We’re excited."